Key statistics
As of last trade, Akeso Inc (9926:HKG) traded at 98.80, 63.04% above the 52 week low of 60.60 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 99.50 |
|---|---|
| High | 99.50 |
| Low | 97.20 |
| Bid | 98.65 |
| Offer | 99.00 |
| Previous close | 99.55 |
| Average volume | 4.56m |
|---|---|
| Shares outstanding | 921.14m |
| Free float | 717.29m |
| P/E (TTM) | -- |
| Market cap | 96.44bn HKD |
| EPS (TTM) | -1.09 HKD |
Data delayed at least 15 minutes, as of Mar 04 2026 01:42 GMT.
More ▼
- Summit Therapeutics to Present at Upcoming Investor Conferences
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
- Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
- Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
More ▼
